A New Algorithm to Reduce Inappropriate Therapy in the S‐ICD System

Abstract

A new algorithm that uses correlation of the existing complex to previous complexes reduced TWOS episodes by approximately 40%. The algorithm has potential for a clinically meaningful decrease in inappropriate shocks.

Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center

“…congenital heart disease, Brugada and long QT syndromes), while in TV-ICD TWOS is involved in about 20% of cases [4,5,25,26]. This aspect is important because it underlies the importance of exercise testing shortly after the implantation, as well as adopting a detailed patient screening practice with selection of the optimal sensing vector in different positions to reduce the risk of TWOS [28,29]. Careful screening, software updates and template selection has reduced the occurrence of inappropriate shocks with the current S-ICDs when compared with the earlier experiences [29].…”

ICD Therapy for Primary Prevention in Hypertrophic Cardiomyopathy

“…The advent of dual zone programming is reported to reduce the rates of inappropriate sensing by up to 40 %. 73 Patients with HCM may provide a special challenge in avoiding inappropriate shocks due to the progressive nature of hypertrophy and the activity level of younger patients. Both the QRS complex and T-wave may change in amplitude and morphology as the ventricle hypertrophies in HCM.…”

Efficacy and Myocardial Injury With Subcutaneous Implantable Cardioverter Defibrillators – Computer Simulation of Defibrillation Shock Conduction –

“…Inappropriate shocks with S-ICD systems have been reduced using ICD programming such as the recognition of supraventricular tachycardia, 20 and T wave oversensing. 21 The influence of a coil lead placed at the right parasternal margin on the atrial sensing remains unknown and has never been reported. Given that a coil lead placed at the right parasternal margin may reduce the DFT of S-ICD systems, a clinical trial is necessary to study this novel lead configuration.…”